Facilities
- Home
- Facilities
Smart. Secure. Scientific. Scalable
Trusted Platform for Progress
Our Success Stories
Manufactoring Units
All three units are WHO-GMP and ISO 9001:2015 certified. Unit 2 is additionally pursuing CE marking for nasal, ophthalmic, medical device and wound dressing products, currently shown as in progress. No USFDA or EU-GMP certification is listed for the current facilities.
Dosage forms handled across the network: tablets, capsules, injections, drops, and ointments/external preparations, a category that also covers oral jelly and aerosol formats. Between them the three units cover oral solids, sterile injectables and topical/liquid formulation, which is a broader spread than most single-site manufacturers can offer.
Total production capacity: approximately 4.4 billion units a year, made up of roughly 2,012 million tablets, 1,857 million capsules, 515 million units of ointment and external preparation, 22 million drops and 7 million injections. Capsule and tablet capacity together account for the large majority of network output, with injections representing the network’s smallest but most specialised line, run exclusively out of Unit 3’s sterile vial suite.
01
Unit 1, Vasai, Mumbai
Operational since 1990, the Vasai facility is HAB Pharma's oldest manufacturing site and the plant the company was originally built around. It consists of a single owned production block of roughly 1,200 square metres of built-up area on about 500 square metres of owned land, and is staffed by 119 on-roll employees. Because the entire site sits under one block and one roof, it runs as a compact, tightly supervised oral-solid operation rather than a multi-block campus.
Capabilities
Dosage forms: tablets and capsules. Production lines and technologies: granulation, compression, coating and capsule filling, covering the full sequence from raw powder blend through to a finished, coated tablet or filled capsule. Packaging capabilities: blister packing on both online and offline lines, giving the site flexibility on run size and pack format, plus drum, octagonal and dry blending for bulk pre-mix and powder handling ahead of compression or filling.
Capacity
672 million tablets and 226 million capsules annually. Output from Vasai is directed to South Asia, Africa and Southeast Asia.
Certifications
02
Unit 2, Selaqui, Dehradun
Established in 2008 on the Selaqui campus in Uttarakhand, this facility runs across two blocks, Block A, an owned block of roughly 6,000 square metres, and Block B, a leased block of roughly 4,000 square metres, sitting on a combined 2,427 square metres of owned land and 850 square metres of leased land. The unit employs 257 people on roll, making it the largest of the three by headcount. Splitting the site into an owned core block and a leased secondary block has let the company add aerosol and topical capacity (Block B) without having to expand or re-license the original formulation block (Block A).
Capabilities
Dosage forms: tablets, capsules, drops, and ointments/external preparations, including oral jelly and aerosol formats, the widest dosage-form range of any single unit in the network. Production lines and technologies: granulation, compression, coating and capsule filling for oral solids; dedicated formulation manufacturing, eye drop filling and tube filling for liquids and topicals; and aerosol filling and general manufacturing in Block B. Packaging capabilities: blister packing across online and offline lines, pouch sealing for sachet formats, and tube and aerosol-ready packaging for the unit's liquid and topical output.
Capacity
832 million capsules, 582 million tablets, 450 million units of ointment and external preparation (including oral jelly and aerosol) and 22 million drops annually.
Certifications
03
Unit 3, Selaqui, Dehradun
The newest facility in the network, operational since 2016, sits across three phases on the same Selaqui campus as Unit 2: Phase 1 Beta, an owned block of roughly 3,011 square metres; Phase 2 General, an owned block of roughly 4,324 square metres; and Phase 3 Cepha, a leased block of roughly 2,703 square metres. Together these sit on 1,519 square metres of owned land and 1,158 square metres of leased land, with 240 people on roll. This is the only unit in the network built with a dedicated sterile suite, which is what allows HAB Pharma to manufacture injectables in-house rather than sourcing them externally.
Capabilities
Dosage forms: tablets, capsules, injections, and ointments/external preparations, including aerosol formats. Production lines and technologies: in Phase 1 Beta, vial washing, sterilization, filling, inspection and labelling for injectables, alongside granulation, compression, coating, capsule filling and hand filling for oral solids; in Phase 2 General, granulation, compression, coating, capsule filling, tube filling, aerosol filling and liquid filling; and in Phase 3 Cepha, a focused oral-solid line covering granulation, compression, coating and capsule filling. Packaging capabilities: blister packing across all three phases, plus tube and aerosol filling and packing in Phase 2.
Capacity
799 million capsules, 758 million tablets, 65 million units of ointment and external preparation and 7 million injections annually.
Certifications
Quality & Compliance
01
Quality control systems
All three facilities operate under a shared quality management framework rather than site-specific standards. In-process checks are built into each stage of production, granulation, compression, coating and filling, so deviations are caught at the point they occur rather than only at final release. Batch release itself is gated on documented inspection at every one of those stages, which keeps the release decision consistent regardless of which block or unit produced the batch.
02
Regulatory compliance
All three units hold WHO-GMP and ISO 9001:2015 status, the baseline regulatory position across the network. Unit 2 is additionally pursuing CE marking, specifically for its nasal, ophthalmic, medical device and wound dressing lines, which would extend the network's regulatory reach into markets that require CE-marked medical devices alongside conventional pharmaceutical registrations. No USFDA or EU-GMP certification currently applies to the facilities described here.
03
Audits & certifications
Running a shared quality standard across three units, rather than a separate standard per site, has let HAB Pharma support repeat regulatory and customer audits without needing site-specific rework each time an auditor visits a different block. That consistency underpins the group's export reach into South Asia, Africa, Southeast Asia, Latin America and the Middle East, where customers and regulators alike expect the same documented process discipline whichever HAB Pharma facility a given batch was produced at.
Talk to the Facilities Team
Whether you’re evaluating HAB Pharma for contract manufacturing, checking available capacity for a specific dosage form, confirming certification for a regulated market, or simply want to see a plant in person, the facilities team can walk you through site-specific detail that isn’t captured in this overview, current line utilisation, lead times, and product-fit for your formulation.
- A-301, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel (West), Mumbai – 400013.
- info@habpharma.in
- 022-66261400
Follow Us
Home
- Contract Manufacturing
- Manufacturing
- Sales & Distribution
- Export
R&D
- Quality Control
- Drug Discovery